**Chapter 8**

*Advances in Precision Medicine Oncology*

[70] Bever CS, Dong JX, Vasylieva N, Barnych B, Cui Y, Xu ZL, et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Anal Bioanal Chem. 2016;

[71] Tsunekawa N, Higashi N, Kogane Y, Waki M, Shida H, Nishimura Y, et al. Heparanase augments inflammatory chemokine production from colorectal carcinoma cell lines. Biochem Biophys Res Commun. 2016; 469(4):878-83.

[72] Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al.

and antitumor activity of CARredirected T lymphocytes. Nat Med.

[73] Dudley ME, Gross CA,

[74] Bonifant CL, Jackson HJ,

Ther Oncolytics. 2016; 3:16011.

Biol Ther. 2019; 19(8):811-27.

Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol

[75] Magalhaes I, Carvalho-Queiroz C, Hartana CA, Kaiser A, Lukic A, Mints M, et al. Facing the future:

challenges and opportunities in adoptive T cell therapy in cancer. Expert Opin

2015; 21(5):524-9.

16(24):6122-31.

Heparanase promotes tumor infiltration

Langhan MM, Garcia MR, Sherry RM, Yang JC, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;

408(22):5985-6002.

**138**
